Blair Westerly, MD Effective treatment for idiopathic pulmonary fibrosis continues to elude patients and clinicians alike. Multiple classes of medications have been studied, none with convincing data demonstrating efficacy. Because of the proposed contribution of endothelin-1 to the pathogenesis of IPF, receptor antagonists of this growth factor have previously been evaluated in IPF, but with disappointing results: bosentan (Tracleer) failed to improve IPF outcomes in
Macitentan for IPF falls short in MUSIC trial
Macitentan for IPF falls short in MUSIC trial
Macitentan for IPF falls short in MUSIC trial
Blair Westerly, MD Effective treatment for idiopathic pulmonary fibrosis continues to elude patients and clinicians alike. Multiple classes of medications have been studied, none with convincing data demonstrating efficacy. Because of the proposed contribution of endothelin-1 to the pathogenesis of IPF, receptor antagonists of this growth factor have previously been evaluated in IPF, but with disappointing results: bosentan (Tracleer) failed to improve IPF outcomes in